https://kenyamazaki.com/2026/05/19/city/Ken リクルターブログja2026-05-18T20:00:00+00:00City Therapeuticsの臨床試験とIPOの可能性ARCH VENTURE PARTNERS, Regeneron, Biotechnology, RNA interference, Pharmaceuticals, City Therapeutics, Therapeutics, RNAi, Pipeline, Drug Discovery, Biopharma, Clinical Trial, Biotech, Next Generation RNAi, RNAi Platform, IND, Stargardt Disease, Ophthalmology, Series A, CITY-RBP4, John Maraganore, Venture Capital, Biogen, IPO, M&Ahttps://kenyamazaki.com/wp-content/uploads/2026/05/pexels-photo-36925382.jpeg?w=84